Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Net Cash Flow (2016 - 2025)

Iovance Biotherapeutics has reported Net Cash Flow over the past 12 years, most recently at $4.3 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $4.3 million for Q4 2025, up 109.17% from a year ago — trailing twelve months through Dec 2025 was $45.9 million (up 178.1% YoY), and the annual figure for FY2025 was $45.9 million, up 178.1%.
  • Net Cash Flow for Q4 2025 was $4.3 million at Iovance Biotherapeutics, down from $26.4 million in the prior quarter.
  • Over the last five years, Net Cash Flow for IOVA hit a ceiling of $311.8 million in Q1 2023 and a floor of -$249.7 million in Q2 2023.
  • Median Net Cash Flow over the past 3 years was -$17.9 million (2024), compared with a mean of -$5.6 million.
  • Biggest five-year swings in Net Cash Flow: crashed 265.78% in 2024 and later surged 238.0% in 2025.
  • Iovance Biotherapeutics' Net Cash Flow stood at -$155.9 million in 2023, then surged by 69.64% to -$47.3 million in 2024, then soared by 109.17% to $4.3 million in 2025.
  • The last three reported values for Net Cash Flow were $4.3 million (Q4 2025), $26.4 million (Q3 2025), and -$40.4 million (Q2 2025) per Business Quant data.